|
Clinicopathological and genetic characteristics of AA CRC cases |
|||||
| African Americans |
|||||
|
|
|||||
| All |
non-MSI-H |
MSI-H |
Odds Ratio (95% CI) |
P |
|
|
|
|||||
| Number of patients |
95 |
66 (69)a |
29 (31)a |
||
| Mean Age |
65.7+15.0 - |
65.2+14.0 - |
65.9+17.5 - |
0.84 |
|
| Gender |
0.39 |
||||
| Female |
56 (59) |
37 (57) |
19 (66) |
1 |
|
| Male |
39 (41) |
29 (43) |
10 (34) |
0.67(0.27–1.67) |
|
| Site |
0.47 |
||||
| Distal |
38 (40) |
28 (43) |
10 (34) |
1 |
|
| Proximal |
57 (60) |
38 (57) |
19 (66) |
0.71(0.29–1.77) |
|
| Mucin Production |
95 |
0.15 |
|||
| None |
68 (72) |
51(77) |
17(58) |
1 |
|
| < 50% |
15 (15) |
9 (14) |
6 (21) |
2.0(0.62–6.44) |
|
| > 50% |
12 (13) |
6 (9) |
6(21) |
3.0(0.85–10.55) |
|
| Differentiation |
90 |
0.47 |
|||
| Well |
3 (3) |
2 (3) |
1 (3) |
1 |
|
| Moderate |
71 (79) |
51 (83) |
20 (72) |
0.64(0.5–8.62) |
|
| Poor |
16 (18) |
9 (14) |
7 (25) |
0.5(0.17–1.54) |
|
| Stage |
92 |
0.59 |
|||
| Stage 1 |
8 (9) |
7 (11) |
1 (3) |
1 |
|
| Stage 2 |
37 (40) |
24 (38) |
13 (45) |
0.67(0.09–4.93) |
|
| Stage 3 |
35 (38) |
23 (37) |
12 (41) |
1.08(0.27–4.29) |
|
| Stage 4 |
12 (13) |
9 (14) |
3 (11) |
0.8(0.2–3.27) |
|
| BRAF |
82 |
0.00 |
|||
| wild type |
74 (90) |
59 (98) |
15 (68) |
||
| V600E |
8 (10) |
1 (2) |
7 (32) |
27.5(3.1–241.3) |
|
| hMLH1 methylation (MSP) |
70 |
0.33 |
|||
| Unmethylation |
4 (6) |
2 (4) |
2 (10) |
1 |
|
| Methylation |
66 (94) |
48 (96) |
18 (90) |
0.38(0.5–2.87) |
|
| p16 methylation (MSP) |
47 |
0.37 |
|||
| Unmethylation |
28 (60) |
14 (54) |
14 (67) |
1 |
|
| Methylation |
19 (40) |
12 (46) |
7 (33) |
0.58(0.18–1.92) |
|
| hMLH1 expression by IHC |
76 |
0.00 |
|||
| Normal |
50 (65) |
45 (83) |
5 (23) |
1 |
|
| Negative |
26 (35) |
9 (17) |
17 (77) |
16.67(5–50) |
|
| hMSH2 expression by IHC |
74 |
0.29 |
|||
| Normal |
66 (89) |
46 (87) |
20 (95) |
1 |
|
| Negative |
8 (11) |
7 (13) |
1 (5) |
0.33(0.04–2.86) |
|
Brim et al. Molecular Cancer 2008 7:68 doi:10.1186/1476-4598-7-68 |
|||||